Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

RxSight (RXST) Shares Issued (2020 - 2026)

RxSight filings provide 6 years of Shares Issued readings, the most recent being $4.0 million for Q4 2025.

On a quarterly basis, Shares Issued fell 95.62% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 96.35% decrease, with the full-year FY2025 number at $4.0 million, down 96.35% from a year prior.
Shares Issued hit $4.0 million in Q4 2025 for RxSight, up from -$2.8 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $90.3 million in Q4 2024 to a low of -$44.6 million in Q4 2023.
Median Shares Issued over the past 5 years was $985500.0 (2021), compared with a mean of $4.7 million.
Biggest five-year swings in Shares Issued: crashed 346.4% in 2022 and later skyrocketed 1234.17% in 2024.
RxSight's Shares Issued stood at $764000.0 in 2021, then plummeted by 140.31% to -$308000.0 in 2022, then crashed by 14373.05% to -$44.6 million in 2023, then surged by 302.51% to $90.3 million in 2024, then plummeted by 95.62% to $4.0 million in 2025.
The last three reported values for Shares Issued were $4.0 million (Q4 2025), -$2.8 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.